natgillin/translations-raw huggingface dataset:
Tablet core: mannitol (E421), dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl-cellulose (E463), magnesium stearate (E470b)
Jedro tablete: manitol (E421), kalcijev hidrogenfosfat, natrijev karboksimetilškrob, hidroksipropil-celuloza (E463), magnezijev stearat (E470b).
Tablet core: mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose
Jedro tablete: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delno substituirana hidroksipropilceluloza
Tablet core: mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose,
Jedro tablete: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delno substituirana hidroksipropilceluloza
Tablet core: mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose,
Jedro tablete: manitol (E421), hidrogenirano ricinusovo olje, mikrokristalna celuloza, makrogol 6000 in delnosubstituirana hidroksipropilceluloza
Tablet core: mannitol (E421), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil (see section 2 ‘DuoPlavin contains hydrogenated castor oil’), stearic acid and colloidal anhydrous silica
Jedro tablete: manitol (E421), makrogol 6000, mikrokristalna celuloza, nizko substituirana hidroksipropilceluloza, koruzni škrob, hidrogenirano ricinusovo olje (glejte poglavje 2 ‘Zdravilo DuoPlavin vsebuje hidrogenirano ricinusovo olje’), stearinska kislina in brezvodni koloidni silicijev dioksid.
Tablet core: Methylcellulose, crospovidone, magnesium stearate.
Jedro tablete: metilceluloza, krospovidon, magnezijev stearat.
Tablet core: microcrystalline cellulose (E460(i)), lactose monohydrate, copovidone, croscarmellose sodium, colloidal anhydrous silica (E551), magnesium stearate (E470b).
Jedro tablete: mikrokristalna celuloza (E460(i)), laktoza monohidrat, kopovidon, premreženi natrijev karmelozat, koloidni brezvodni silicijev dioksid (E551), magnezijev stearat (E470b).
Tablet core: microcrystalline cellulose (E460), anhydrous calcium hydrogen phosphate, croscarmellose sodium, hypromellose (E464), magnesium stearate (E572).
Jedro tablete: mikrokristalna celuloza (E460), kalcijev hidrogenfosfat, brezvodni, premreženi natrijev karmelozat, hipromeloza (E464), magnezijev stearat (E572).
Tablet core: Microcrystalline cellulose Croscarmellose sodium Colloidal anhydrous silica Magnesium stearate
Jedro tablete: mikrokristalna celuloza natrijev karmelozat, premreženi brezvoden koloidni silicijev dioksid magnezijev stearat
Tablet core: Microcrystalline cellulose Croscarmellose sodium Lactose monohydrate Hypromellose
Jedro tablete mikrokristalna celuloza
Tablet core: Microcrystalline cellulose Croscarmellose sodium Povidone
Jedro tablete mikrokristalna celuloza
Tablet core: Microcrystalline cellulose Lactose monohydrate Croscarmellose sodium Magnesium stearate
Jedro tablete: mikrokristalna celuloza laktoza monohidrat premreženi natrijev karmelozat magnezijev stearat
Tablet core: microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate,
Jedro tablete: mikrokristalna celuloza, brezvodni kalcijev hidrogenfosfat, premreženi natrijev karmelozat, magnezijev stearat.
Tablet core: microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate.
Jedro tablete: mikrokristalna celuloza, brezvodni kalcijev hidrogenfosfat, premreženi natrijev karmelozat, magnezijev stearat.
Tablet core: microcrystalline cellulose, calcium hydrogen phosphate anhydrous, croscarmellose sodium, magnesium stearate.
Jedro tablete: mikrokristalna celuloza, brezvodni kalcijev hidrogenfosfat premreženi natrijev karmelozat, magnezijev stearat.
Tablet core: microcrystalline cellulose, calcium hydrogen phosphate anhydrous, croscarmellose sodium, magnesium stearate.
Jedro tablete: mikrokristalna celuloza, brezvodni kalcijev hidrogenfosfat, premreženi natrijev karmelozat, magnezijev stearat.
Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil
Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000 in hidrogenirano ricinusovo olje
Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil.
Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000, hidrogenirano ricinusovo olje
Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000, hydrogenated castor oil
Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000 in hidrogenirano ricinusovo olje
Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000, hydrogenated castor oil (see section 2 ‘Clopidogrel Dura contains hydrogenated castor oil’)
Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000 in hidrogenirano ricinusovo olje (glejte poglavje 2: »Zdravilo
Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000, hydrogenated castor oil (see section 2 ‘Clopidogrel Mylan contains hydrogenated castor oil’)
Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000 in hidrogenirano ricinusovo olje (glejte poglavje 2: »Zdravilo Klopidogrel Mylan vsebuje tudi hidrogenirano ricinusovo olje«)
Tablet core: microcrystalline cellulose, croscarmellose sodium, talc, hydrophobic colloidal silica, magnesium stearate.
Jedro tablete: mikrokristalna celuloza, natrijeva kroskarmeloza, smukec, hidrofobni koloidni silicijev dioksid, magnezijev stearat.
Tablet core: microcrystalline cellulose, crospovidone type A, magnesium stearate, silica colloidal anhydrous
Jedro tablete: mikrokristalna celuloza, krospovidon tipa A, magnezijev stearat, koloidni brezvodni silicijev dioksid
Tablet core: Microcrystalline cellulose, hydroxypropylcellulose (E463), mannitol (E421), crospovidone (type A), citric acid monohydrate, macrogol 6000, stearic acid, talc
Jedro tablete: mikrokristalna celuloza, hidroksipropilceluloza (E463), manitol (E421), krospovidon (vrsta A), citronska kislina monohidrat, makrogol 6000, stearinska kislina, smukec.
Tablet core: microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylcellulose (low substituted), colloidal anhydrous silica, crospovidone (polyplasdone XL-10 Pharmaceutical Grade), magnesium stearate
Jedro tablete: mikrokristalna celuloza, hidroksipropilceluloza, hidroksipropilceluloza (delno substituirana) koloidni silicijev dioksid, krospovidon (farmacevtski poliplasdon XL-10), magnezijev stearat
Tablet core: microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylcellulose (low substituted), colloidal anhydrous silica, crospovidone (polyplasdone XL-10 Pharmaceutical Grade), magnesium stearate
Jedro tablete: mikrokristalna celuloza, hidroksipropilceluloza, hidroksipropilceluloza (delno substituirana), koloidni silicijev dioksid, krospovidon (farmacevtski poliplasdon XL-10), magnezijev stearat
Tablet core: Microcrystalline cellulose, Magnesium stearate, Colloidal silicon dioxide.
Jedro tablete: mikrokristalna celuloza, magnezijev stearat, koloiden silicijev dioksid.
Tablet core: microcrystalline cellulose, sodium starch glycollate (gluten free), magnesium stearate
Jedro tablete: mikrokristalna celuloza, natrijev karboksimetilškrob (brez glutena) in magnezijev stearat.
Tablet Core: microcrystalline cellulose, sodium starch glycollate (type A), magnesium stearate.
Jedro tablete: Mikrokristalna celuloza, natrijev karboksimetilškrob (vrsta A), magnezijev stearat.
Tablet core: Microcrystalline cellulose, starch (pregelatinised), mannitol, talc, magnesium stearate.
Jedro tablete: mikrokristalna celuloza, škrob (predgelirani), manitol, smukec, magnezijev stearat.
Tablet core: Povidone
Jedro tablete: povidon predgelirani škrob poloksamer 188
Tablet core: povidone K30, magnesium stearate.
Jedro tablete: povidon K30, magnezijev stearat.
Tablet core: Povidone Polysorbate 80 Anhydrous lactose Lactose monohydrate Crospovidone Magnesium stearate
Jedro tablete: povidon polisorbat 80 brezvodna laktoza laktoza monohidrat krospovidon magnezijev stearat
Tablet core: povidone, pregelatinized starch (maize), poloxamer 188, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and magnesium stearate.
Jedro tablete: povidon, predgelirani škrob (koruzni), poloksamer 188, mikrokristalna celuloza, premreženi natrijev karmelozat, koloidni brezvodni silicijev dioksid, magnezijev stearat.
Tablet core: talc (E553b), anhydrous lactose, croscarmellose sodium (E468), hypromellose (E464), cellulose microcrystalline (E460), magnesium stearate (E572).
Jedro tablete: smukec (E553b), brezvodna laktoza, premrežen natrijev karmelozat (E468), hipromeloza (E464), mikrokristalna celuloza(E460), magnezijev stearat (E572).
tablet core; microcrystalline cellulose, sodium starch glycollate (gluten free), magnesium stearate, colloidal silicon dioxide tablet film-coat; hypromellose, titanium dioxide, macrogol 400 and polysorbate 80.
jedro tablete: mikrokristalna celuloza, natrijev karboksimetilškrob (brez glutena), magnezijev stearat, koloidni silicijev dioksid, filmska obloga: hipromeloza, titanov dioksid, makrogol 400 in polisorbat 80.
Tablet cores for 5/10/15/20 mg film-coated tablets
Jedro tablete za 5/10/15/20 mg filmsko obložene tablete
Tablet cores for 5/10/15/20 mg film-coated tablets Lactose monohydrate
Jedro tablete pri 5/10/15/20 mg filmsko obloženih tabletah laktoza monohidrat
Tablet cores for 5/10/15/20 mg film-coated tablets:
Jedro tablete pri 5/10/15/20 mg filmsko obloženih tabletah:
Tablet dose
odmerek filmsko obloženih tablet
Tablet film coat Hypromellose 3cP Hypromellose 6cP Titanium dioxide Macrogol 400
Filmska obloga tablete hipromeloza 3cP, hipromeloza 6cP, titanov dioksid, makrogol 400,
Tablet film coat: Hypromellose (E464), titanium dioxide (E171), macrogol 400, polysorbate 80
Filmska obloga tablete: hipromeloza (E464) titanov dioksid (E171) makrogol 400 polisorbat 80
Tablet film coating - CHAMPIX 0.5 mg film-coated tablets Hypromellose
Filmska obloga tablete - CHAMPIX 0,5 mg filmsko obložene tablete
Tablet film coating - CHAMPIX 1 mg film-coated tablets Hypromellose
Filmska obloga tablete - CHAMPIX 1 mg filmsko obložene tablete
Tablet film-coat Hypromellose (E464) Titanium dioxide (E171) Polyethylene glycol Polysorbate 80 (E433) Iron oxide red (E172)
Filmska obloga tablete hipromeloza (E464) titanov dioksid (E171) polietilenglikol polisorbat 80 (E433) rdeči železov oksid (E172)
Tablet film-coat Hypromellose 3cP Hypromellose 6cP Polysorbate 80
Filmska obloga tablete: hipromeloza 3cP hipromeloza 6cP polisorbat 80
Tablet film-coat polyvinyl alcohol, macrogol, talc, titanium dioxide (E171), iron oxide yellow (E172)
filmska obloga tablete polivinilalkohol, makrogol, smukec, titanov dioksid (E171), rumeni železov oksid (E172)
Tablet film-coat: Hypromellose (E464), Titanium dioxide (E171), Black iron oxide (E172), Macrogol, Polysorbate 80
Filmska obloga tablete: hipromeloza (E464) titanov dioksid (E171) črni železov oksid (E172) makrogol polisorbat 80
Tablet film-coating: hypromellose (E464), titanium dioxide (E171), macrogol 400, iron oxide black (E172) and iron oxide red (E172).
Filmska obloga tablete: hipromeloza (E464), titanov dioksid (E171), makrogol 400, črni železov oksid (E172) in rdeči železov oksid (E172).
Tablet film-coating: hypromellose (E464), titanium dioxide (E171), talc, macrogol 400, and iron oxide yellow (E172).
Filmska obloga tablete: hipromeloza (E464), titanov dioksid (E171), smukec, makrogol 400 in rumeni železov oksid (E172).
Tablet film-coating: polyvinyl alcohol (E1203), polyethylene glycol 3350, talc (E553b), titanium dioxide (E171) and red iron oxide (E172).
Filmska obloga tablete: polivinilalkohol (E1203), polietilenglikol 3350, smukec (E553b), titanov dioksid (E171), rdeči železov oksid (E172).
Tablet film-coating: polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol
Filmska obloga tablete: polivinilalkohol (E1203), titanov dioksid (E171), polietilenglikol
tablet Oprymea 0.18 mg three times a day tablets Oprymea 0.088 mg three times a day tablet Oprymea 0.35 mg three times a day tablets Oprymea 0.18 mg three times a day
tableta zdravila Oprymea po 0,18 mg 3-krat na dan ALI tableti zdravila Oprymea po 0,088 mg 3-krat na dan tableta zdravila Oprymea po 0,35 mg 3-krat na dan ALI tableti zdravila Oprymea po 0,18 mg 3-krat na dan
Tablet or Oral suspension
Tableta ali peroralna suspenzija
tablet SIFROL 0.18 mg OR tablets SIFROL tablet SIFROL 0.35 mg OR tablets SIFROL 0.18 mg OR
tableta zdravila SIFROL po 0,18 mg tableti zdravila SIFROL po 0,088 mg tableta zdravila SIFROL po 0,35 mg tableti zdravila SIFROL po 0,18 mg
Tablet strength (mg)
Moč tablete (mg)
Tablet.
Diskinezija
tablets
tablet
tablets
tableti
tablets (7 x 5 mg + 7 x 10 mg + 7 x 15 mg
10 mg + 7 x 15 mg +
tablets (multipack) 126 (9 x 14)
126 (9 x14) tablet
tablets 4 tablets
2 tableti 4 tablete
Tablets 90 tablets
tablete 90 tablet
Tablets and the oral suspension can be interchanged at the same dose, but patients should be monitored during the switch-over period for any side effects.
Jemanje tablet ali peroralne suspenzije se lahko izmenjuje v istem odmerku, vendar je treba bolnike ob prehodu na drugo obliko zdravila nadzorovati zaradi neželenih učinkov.
Tablets are engraved with “nGL” on one side and the strength of the tablet on the other.
Tablete imajo vtisnjeno oznako “nGL” na eni strani in jakost tablete na drugi strani.
Tablets are round, beige to brown, non-divisible and with imprints “NA” on one side and “AK” on the other side.
Tablete so okrogle, bež do rjave barve, nedeljive in z vtisnima oznakama »NA« na eni in »AK« na drugi strani.
Tablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots.
Tablete so okrogle, rahlo izbočene, svetlo rumene barve z morebitnimi posameznimi rumenimi pikami.
Tablets are round, slightly biconvex, yellow marbled tablets with possible individual spots.
Tablete so okrogle, rahlo izbočene, rumene barve z morebitnimi posameznimi rumenimi pikami.
Tablets are yellow, oval-shaped, film-coated tablets, size 8.48 mm x 4.76 mm, with “351” on one side and the MSD logo on the other side.
Tablete so rumene, ovalne, filmsko obložene tablete, velikosti 8,48 mm x 4,76 mm, z oznako "351" na eni strani in MSD logotipom na drugi strani.
Tablets available in aluminum foil blisters.
Tablete so na voljo v pretisnih omotih iz aluminijske folije.
Tablets can be administered with or without food.
Tablete lahko dajamo s hrano ali brez.
Tablets may be taken with or without food.
Tablete lahko vzamete s hrano ali brez nje.
Tablets must be chewed and taken with meals.
Tablete je treba prežvečiti in jih jemati z obroki.
Tablets must be chewed and taken with meals.
Tablete je treba prežvečiti in jih vzeti s hrano.
Tablets must only be given if the child is able to swallow tablets.
Tablete se sme uporabiti le, če jih je otrok sposoben pogoltniti.
Tablets of lower strengths are available and your doctor may have prescribed a certain combination of tablets to construct the appropriate dosing regimen.
Obstajajo tudi tablete drugih jakosti in zdravnik lahko predpiše določeno kombinacijo tablet, da doseže primeren odmerek.
Tablets packaged in:
Tablete, pakirane v:
Tablets per dose
Število tablet na odmerek
Tablets should be kept in the blister package until administration.
Tablete hranite v pretisnem omotu do odmerjanja.
Tablets should be kept in the blister packs until required and the blisters should be kept in the carton.
Tablete je treba do uporabe hraniti v pretisnem omotu, omot pa v škatlici.
Tablets should be swallowed whole with a glass of water (180 to 240 ml) while the patient is sitting or standing in an upright position.
Tablete je treba pogoltniti cele in popiti poln kozarec vode (180 do 240 ml); bolnik mora pri tem stati ali vzravnano sedeti.
Tablets should be swallowed whole with a glass of water (180 to 240 ml) while the patient is sitting or standing in an upright position.
Tablete je treba pogoltniti cele, s kozarcem vode (180 do 240 ml), bolnik mora pri tem stati ali pokončno sedeti.
Tablets should be swallowed without chewing with a glass of water.
Tablete je treba pogoltniti cele z vodo, brez žvečenja.
Tablets should be taken whole and not divided.
Tablete je treba vzeti cele in se jih ne sme deliti.
tablets)
obložena tableta)
Tablets’ core
Jedro tablet
Tablulated list of adverse reactions in head and neck cancer for Docetaxel 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tabelarični prikaz neželenih učinkov zdravljenja z zdravilom Docetaksel 75 mg/m2 pri raku glave in vratu v kombinaciji s cisplatinom in 5-fluorouracilom
Tablulated list of adverse reactions in prostate cancer for Docetaxel 75 mg/m² in combination with prednisone or prednisolone
Tabelarični prikaz neželenih učinkov zdravljenja z zdravilom Docetaksel 75 mg/m2 pri raku prostate v kombinaciji s prednizonom ali prednizolonom
Tabular Listing of adverse events:
Navedba neželenih učinkov v preglednici:
Tabulated information on dosing by body weight of patient.
Informacije o odmerjanju glede na telesno maso bolnika v preglednicah.
Tabulated list of ADRs
Tabelaričen prikaz neželenih učinkov
Tabulated list of adverse drug reactions
Tabelarični prikaz neželenih učinkov
Tabulated list of adverse events
Neželeni učinki v obliki preglednice
Tabulated list of adverse reaction
Seznam neželenih učinkov
Tabulated list of adverse reactions
Neželeni učinki v obliki preglednice
Tabulated list of adverse reactions
Neželeni učinki v obliki razpredelnice
Tabulated list of adverse reactions
Neželeni učinki v obliki tabele
Tabulated list of adverse reactions
Neželeni učinki v preglednici
Tabulated list of adverse reactions
Neželeni učinki, navedeni v preglednici
Tabulated list of adverse reactions
Neželeni učinki, prikazani v preglednici
Tabulated list of adverse reactions
Povzetek neželenih učinkov zdravila v preglednici
Tabulated list of adverse reactions
Povzetek neželenih učinkov, prikazan v preglednicah
Tabulated list of adverse reactions
Preglednica neţelenih reakcij
Tabulated list of adverse reactions
Preglednicaneželenih učinkov
Tabulated list of adverse reactions
Razvrščeni neželeni učinki
Tabulated list of adverse reactions
rosuvastatin:
Tabulated list of adverse reactions
Seznam neželenih reakcij v obliki preglednice
Tabulated list of adverse reactions
Seznam neželenih učinkov je naveden v preglednici.
Tabulated list of adverse reactions
Seznam neželenih učinkov prikazan v preglednici
Tabulated list of adverse reactions
Seznam neželenih učinkov v tabeli
Tabulated list of adverse reactions
Seznam neželenih učinkov zdravila v preglednici
Tabulated list of adverse reactions
Seznam neželenih učinkov, prikazan v preglednicah
Tabulated list of adverse reactions
Seznam neželenih učinkov, prikazan v preglednici
Tabulated list of adverse reactions
Seznam neželenihučinkov, prikazan v preglednici
Tabulated list of adverse reactions
Tabela s seznamom neželenih učinkov
Tabulated list of adverse reactions
Tabela z neželenimi učinki
Tabulated list of adverse reactions
Tabelarični povzetek neţelenih učinkov
Tabulated list of adverse reactions
Tafla yfir aukaverkanir
Tabulated list of adverse reactions
Vsi neželeni učinki zdravila Trevaclyn
Tabulated list of adverse reactions (Table 1)
Seznam neželenih učinkov v preglednici (Preglednica 1)
Tabulated list of adverse reactions - aprepitant
Seznam neželenih učinkov v preglednici - aprepitant
Tabulated list of adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tabelarični prikaz neţelenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Teva Pharma 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki
Tabulated list of adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer – pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaksel 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki
Tabulated list of adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki.
Tabulated list of adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki:
Tabulated list of adverse reactions for adjuvant therapy with TAXOTERE 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom TAXOTERE 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki
Tabulated list of adverse reactions for RCC and DTC studies
Seznam neželenih učinkov v študijah RCC in DTC v obliki preglednice
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom docetaksel 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data.
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaksel 75 mg/m² v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) - kumulativnimi podatki
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer – pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaksel Teva 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) – kumulativni podatki